Monocyte suppressing action of fenofibrate.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 3
Abstract
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-derived proinflammatory cytokines are widely known to beinvolved in the formation and rupture of the atherosclerotic plaque. The aim of our study was to assessthe effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta),interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combinedhyperlipidemia. Fourteen patients with biochemically confirmed type IIb dyslipidemia who did not respondto a low-fat diet were treated with micronized fenofibrate for 1 month. The control group included 12healthy, normolipidemic, age-matched subjects. To accurately evaluate the levels of the inflammatorycytokines, we excluded patients with any inflammatory disease. Monocytes were isolated from peripheralblood before and after the treatment. IL-1beta, IL-6 and MCP-1 release was measured by enzyme-linkedimmunosorbent assay (ELISA) after lipopolysaccharide stimulation. IL-1beta, IL-6 and MCP-1 levels weresignificantly higher in hyperlipidemic patients compared to the control (143.9 +/- 6.5 vs. 74.4 +/- 4.4pg/ml; 8212 +/- 285 vs. 6110 +/- 170 pg/ml; 19.6 +/- 0.9 vs. 12.3 +/- 0.6 ng/ml, respectively). Thirty-dayfenofibrate treatment decreased the release of IL-1beta by 43% (143.9 +/- 6.5 vs. 86.2 +/- 5.9 pg/ml),of IL-6 by 22% (8212 +/- 285 vs. 6330 +/- 234 pg/ml), and of MCP-1 by 29% (19.6 +/- 0.9 vs. 14.0 +/-0.8 ng/ml). The evaluated cytokines were markedly elevated in patients with type IIb dyslipidemia. Effectivefenofibrate therapy had a significant inhibitory effect on the release of monocyte-derived inflammatorycytokines.
Authors and Affiliations
Bogusław Okopień, Jan Kowalski, Robert Krysiak, Krzysztof Łabuzek, Aldona Stachura-Kułach, Andrzej Kułach, Marek Zieliński, Zbigniew Herman
Keywords
Related Articles
- EP ID EP159747
- DOI -
- Views 112
- Downloads 0
Efficacy of bretazenil against cortical epileptic afterdischarges increases during early ontogeny in rats.
The effect of a benzodiazepine partial agonist bretazenil on cortical epileptica fterdischarges was studied in 12-, 18- or 25-day-old rat pups with implanted electrodes. Afterdischarges were induced by low-frequency stim...
Impact of ursolic acid on chronic ethanol-induced oxidative stress in the rat heart.
Oxidative stress plays an important role as a mediator of myocardial damage produced by ethanol. This work was designed to investigate the effect of ursolic acid (UA), a reported radical scavenger and antioxidant, on oxi...
Non-competitive metabotropic glutamate subtype 5 receptor antagonist (SIB-1893) decreases body temperature in rats.
This study examined the effect of (E)-2-methyl-6-(2-phenylethynyl)-pyridine (SIB-1893), a selective non-competitive metabotropic glutamate subtype 5 receptor (mGluR(5)) antagonist, on body temperature in freely moving Wi...
Different effects of nitric oxide synthase inhibitors on convulsions induced by nicotine in mice.
Acute intraperitoneal (ip) administration of N(G)-nitro-L-arginine (NNA, 10, 20 and 40 mg/kg), a non-selective nitric oxide synthase (NOS) inhibitor, significantly and dose-dependently decreased the incidence of convulsi...
Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis.
Nicotinamide N-methyltrasferase (NMMT) catalyzes the conversion of nicotinamide (NA) to 1-methylnicotinamide (MNA). Recent studies have reported that exogenous MNA exerts anti-thrombotic and anti-inflammatory activity, s...